CymaBay Therapeutics (CBAY) Misses Q3 EPS by 3c

CymaBay Therapeutics (NASDAQ: CBAY) reported Q3 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29).

For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79